title: A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies.
abstract: While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear that besides practical and operational challenges, the heterogeneity of cancer and the limited efficacy profile of current immunotherapy platforms are the two main hurdles. Nevertheless, the promising clinical data of several approaches point to a roadmap that carries the promise to significantly advance cancer immunotherapy. A new annual series sponsored by Arrowhead Publishers and Conferences aims at bringing together scientific and business leadership from academia and industry, to identify, share and discuss most current priorities in research and translation of novel immune interventions. This Editorial provides highlights of the first event held earlier this year and outlines the focus of the second meeting to be held in 2013 that will be dedicated to stem cells and immunotherapy.
authors.affiliation: Kite Pharma Inc, Los Angeles, CA, USA. abot@kitepharma.com
authors.forename: Adrian
authors.initials: A
authors.lastname: Bot
authors.forename: Mark
authors.initials: M
authors.lastname: Ahn
authors.forename: Marnix
authors.initials: M
authors.lastname: Bosch
authors.forename: Dirk
authors.initials: D
authors.lastname: Brockstedt
authors.forename: Lisa H
authors.initials: LH
authors.lastname: Butterfield
authors.forename: Andrew
authors.initials: A
authors.lastname: Cornforth
authors.forename: Richard
authors.initials: R
authors.lastname: Harrop
authors.forename: W Martin
authors.initials: WM
authors.lastname: Kast
authors.forename: Richard
authors.initials: R
authors.lastname: Koya
authors.forename: Francesco
authors.initials: F
authors.lastname: Marincola
authors.forename: Kim
authors.initials: K
authors.lastname: Margolin
authors.forename: Candice
authors.initials: C
authors.lastname: McCoy
authors.forename: Graham
authors.initials: G
authors.lastname: Pawelec
authors.forename: John
authors.initials: J
authors.lastname: Rothman
authors.forename: Teresa
authors.initials: T
authors.lastname: Ramirez-Montagut
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Schlom
authors.forename: Pramod
authors.initials: P
authors.lastname: Srivastava
authors.forename: Sarah
authors.initials: S
authors.lastname: Wallis
authors.forename: Steffen
authors.initials: S
authors.lastname: Walter
authors.forename: Ena
authors.initials: E
authors.lastname: Wang
authors.forename: John
authors.initials: J
authors.lastname: Waslif
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D019496:Cancer Vaccines / Q000276:immunology; D002986:Clinical Trials as Topic; D003226:Congresses as Topic; D006412:Hematopoietic Stem Cells; D006801:Humans; D007167:Immunotherapy; D015166:Monitoring, Immunologic; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy*; D014411:Neoplastic Stem Cells / Q000473:pathology; D033581:Stem Cell Transplantation; D057170:Translational Research, Biomedical
chemical_list: D014408:Biomarkers, Tumor; D019496:Cancer Vaccines